Search
Bayer and Pharmafrontiers Ink Global Licensing Deal for Phase I Clinical Trial of PRMT5 Inhibitor
2025-03-26 /
Read about 0 minute
Author：小编
Bayer and Pharmafrontiers have concluded a comprehensive global licensing agreement aimed at collaboratively advancing an oral, small-molecule PRMT5 inhibitor for the treatment of MTAP-deficient tumors. Pursuant to this agreement, Bayer has secured exclusive worldwide rights to develop, manufacture, and market the inhibitor, and has commenced a Phase I clinical trial.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
